Ramsha Khalid

Ms. Ramsha Khalid


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RKRamsha Khalid
Ramsha Khalid
SMsyed mahmood
syed mahmood
ZSZarif Mohamed Sofian
Zarif Mohamed Sofian
AHAyah Rebhi Hilles
Ayah Rebhi Hilles
NHNajihah Hashim
Najihah Hashim
YGYi Ge
Yi Ge
One of the most cutting-edge, effective, and least invasive pharmaceutical innovations is the utilization of microneedles (MNs) for drug delivery, patient monitoring, diagnostics, medicine or vaccine delivery, and other medical procedures (e.g., intradermal vaccination, allergy testing, dermatology, and blood sampling). The MN-based system offers many advantages, such as minimal cost, high medical effectiveness, comparatively good safety, and painless drug application. Drug delivery through MNs can possibly be viewed as a viable instrument for various macromolecules (e.g., proteins, peptides, and nucleic acids) that are not efficiently administered through traditional approaches. This review article provides an overview of MN-based research in the transdermal delivery of hypertensive drugs. The critical attributes of microneedles are discussed, including the mechanism of drug release, pharmacokinetics, fabrication techniques, therapeutic applications, and upcoming challenges. Furthermore, the therapeutic perspective and improved bioavailability of hypertensive drugs that are poorly aqueous-soluble are also discussed. This focused review provides an overview of reported studies and the recent progress of MN-based delivery of hypertensive drugs, paving the way for future pharmaceutical uses. As MN-based drug administration bypasses first-pass metabolism and the high variability in drug plasma levels, it has grown significantly more important for systemic therapy. In conclusion, MN-based drug delivery of hypertensive drugs for increasing bioavailability and patient compliance could support a new trend of hypertensive drug delivery and provide an alternative option, overcoming the restrictions of the current dosage forms.

7 April 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RKRamsha Khalid
Ramsha Khalid
SMsyed mahmood
syed mahmood
ZSZarif Mohamed Sofian
Zarif Mohamed Sofian
ZCzamri chik
zamri chik
YGYi Ge
Yi Ge
Background: Hypertension (HTN) is recognized as a major risk factor for cardiovascular disease, chronic kidney disease, and peripheral artery disease. Valsartan (VAL), an angiotensin receptor blocker drug for hypertension, has been limited due to its poor solubility and poor absorption from the GIT, which leads to low oral bioavailability. Objectives/Method: In the present research, firstly, VAL-loaded nanoliposomes were formulated and optimized using the Box–Behnken design (BBD). Optimized VAL-nanoliposomes were physically characterized and their fate was examined by scanning and transmission microscopy, DSC, FTIR, XRD, and ex vivo studies using rat skin. In vitro studies using human keratinocyte (HaCaT) cells showed a decrease in cell viability as the liposome concentration increased. Secondly, the formulation of VAL-loaded nanoliposomes was integrated into dissolvable microneedles (DMNs) to deliver the VAL transdermally, crossing the skin barrier for better systemic delivery. Results: The optimized nanoliposomes showed a vesicle size of 150.23 (0.47) nm, a ZP of −23.37 (0.50) mV, and an EE% of 94.72 (0.44)%. The DMNs were fabricated using a ratio of biodegradable polymers, sodium alginate (SA), and hydroxypropyl methylcellulose (HPMC). The resulting VAL-LP-DMNs exhibited sharp pyramidal microneedles, adequate mechanical properties, effective skin insertion capability, and rapid dissolution of the microneedles in rat skin. In the ex vivo analysis, the transdermal flux of VAL was significantly (5.36 (0.39) μg/cm2/h) improved by VAL-LP-DMNs. The enhancement ratio of the VAL-LP-DMNs was 1.85. In conclusion, liposomes combined with DMNs have shown high potential and bright prospects as carriers for the transdermal delivery of VAL. Conclusions: These DMNs can be explored in studies focused on in vivo evaluations to confirm their safety, pharmacokinetics profile, and pharmacodynamic efficacy.

20 October 2025 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Open access
PDF file
RKRamsha Khalid
Ramsha Khalid
SMsyed mahmood
syed mahmood
ZSZarif Mohamed Sofian
Zarif Mohamed Sofian
YGYi Ge
Yi Ge
ZCzamri chik
zamri chik
Felodipine (FD), a calcium channel blocker used to manage hypertension, suffers from poor solubility and low oral bioavailability, which limits its therapeutic efficacy. This study proposes a novel strategy to address this limitation by formulating FD-loaded liposomes (FD-LP) integrated into dissolving microneedles (DMNs), utilizing the biodegradable polymer hydroxypropyl methylcellulose (HPMC) for enhanced transdermal delivery. In the present research, firstly, FD-loaded liposomes were formulated by the thin-film rotary evaporation method and later optimized using Box-Behnken Design (BBD). The optimized FD-LP formulation achieved nanosized vesicles with stable zeta potential and high entrapment efficiency. Methylthiazol tetrazolium (MTT) assay using FD-loaded liposomes against human epidermal keratinocytes (HaCaT) revealed a decrease in cell viability as the concentration of liposomes increased. Secondly, formulation of FD-LP infused into HPMC-based dissolving microneedles to deliver the felodipine transdermally. The resulting FD-LP-DMNs displayed sharp pyramidal microneedles with suitable mechanical strength, effective skin insertion capability, and rapid dissolution of MNs in rat skin. Ex-vivo studies demonstrated the transdermal flux of FD was significantly (4.79 ± 0.03 µg/cm2/hr) improved by FD-LP-DMNs as compared to FD-DMNs. The enhancement ratio of FD-LP-DMNs was 2.77. In conclusion, the integration of FD-loaded liposomes into DMNs shows great promise as a delivery platform for the transdermal administration of FD. This DMN array may serve as a potential approach to a controllable, self-administrative, and rapid transdermal delivery system. Graphical Abstract